Administration of apelin ameliorates skeletal muscle atrophy in CKD mice; therefore, targeting the apelin–Apj system could be a promising therapeutic strategy for the management of skeletal muscle atrophy in CKD. The gene discussed is APLN; the disease is muscle atrophy.